Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells.

Cells - 22 Apr 2021

Goveas Liesel, Mutez Eugénie, Chartier-Harlin Marie-Christine, Taymans Jean-Marc

Abstract excerpt

Mutations in the Parkinson's disease (PD) protein Leucine Rich Repeat Kinase 2 (LRRK2) have been under study for more than 15 years and our understanding of the cellular phenotypes for the pathogenic mutant forms of LRRK2 has significantly advanced. In parallel to research on LRRK2 mutations in experimental systems, clinical characterization of patients carrying LRRK2 mutations has advanced, as has the analysis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fibroblasts
Share to Ginkgo biloba and Cashew Applications
Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Parkinson Disease

Share to Parkinson's Disease Mechanisms and Treatments

Share to Phenotype

Source

Open in PubMed Open full text

Identifiers

PMID: 33922322
DOI: 10.3390/cells10050981
PMCID: PMC8145309

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells.PMID 33922322Read ↗

Induced pluripotent stem cell‐based modeling of mutant LRRK 2‐associated Parkinson's diseaseSemantic proximity Read ↗

LRRK2 Expression Is Deregulated in Fibroblasts and Neurons from Parkinson Patients with Mutations in PINK1.Semantic proximity Read ↗

Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson's disease patient fibroblasts.Semantic proximity Read ↗

Generation of fourteen isogenic cell lines for Parkinson's disease-associated leucine-rich repeat kinase (LRRK2).Semantic proximity Read ↗

Disease‐specific phenotypes in dopamine neurons from human iPS‐based models of genetic and sporadic Parkinson's diseaseSemantic proximity Read ↗

How Parkinson's Disease-Linked LRRK2 Mutations Affect Different CNS Cell Types.Semantic proximity Read ↗

Using Patient-Derived Induced Pluripotent Stem Cells to Identify Parkinson’s Disease-Relevant PhenotypesSemantic proximity Read ↗

Fibroblast Biomarkers of Sporadic Parkinson’s Disease and LRRK2 Kinase InhibitionSemantic proximity Read ↗

LRRK2 in Parkinson's disease: function in cells and neurodegeneration.Semantic proximity Read ↗

In Vitro Modeling of Leucine-Rich Repeat Kinase 2 G2019S-Mediated Parkinson's Disease Pathology.Semantic proximity Read ↗

Generation of iPSCs carrying a common LRRK2 risk allele for in vitro modeling of idiopathic Parkinson's disease.Semantic proximity Read ↗

Distinctive genomic signature of neural and intestinal organoids from familial Parkinson's disease patient-derived induced pluripotent stem cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.